COVID-19 Vaccinations in Adolescents (COVA Study)
The COVID-19 pandemic has caused more than 100 million cases and 3 million deaths globally, and over 10,000 cases in Hong Kong. The virus may cause long COVID and multisystem inflammatory syndrome in children. Some emerging virus variants have also been found to be more infectious to teenagers. Children and adolescents under 20 years old are contagious, and infected children may spread the virus to their grandparents. The prolonged suspension of classes and social distancing have also had a negative impact on students. Therefore, children and adolescents urgently need to be immunised against COVID-19.
Timely local data on the reactogenicity and immunogenicity of COVID-19 vaccines in adolescents will inform the public and the government whether the vaccines should be given to adolescents, and allow complete school reopening as soon as possible. This study has been approved by the Institutional Review Board of HKU/Hospital Authority HK West Cluster.
2019冠狀病毒病（COVID-19）大流行在全球造成超過1億宗病例， 300多萬人死亡，而在香港亦有高達1萬多宗病例。兒童感染新冠病毒後可能會導致後遺症和多系統炎症綜合症。有些變種病毒也發現對青少年有更大的感染力。此外，20歲以下的兒童和青少年有較高的傳染性，在家感染同住長者的情況不容忽視。長時間的停課和社交隔離措施亦已對學生造成不良的影響。 因此，兒童和青少年急需接種新冠病毒疫苗。
COVA will recruit 300 healthy adolescents and patients with immune disorders or prior COVID-19 aged 11 years or above, as well as their parents (and unrelated adult controls). At the moment, the families will be offered to receive the BioNTech/Fosun BNT162b2 or SinoVac's CoronaVac. Each family can freely choose the vaccine they receive, given each family member receives the same vaccine. Participants will report adverse reactions and other adverse events following immunisation, and be followed up for immunogenicity assessments and vaccine breakthrough COVID-19 over a period of 3 years. Participants are covered by the Hong Kong government’s COVID-19 vaccine indemnity fund. Recruitment is ongoing for patient groups, and those interested may refer to the registration and contact details below.